News >

Enzalutamide Could Have Pivotal Role in Metastatic Hormone-Sensitive Prostate Cancer

Ellie Leick
Published: Friday, Jul 12, 2019

Christopher J. Sweeney, MBBS

Christopher J. Sweeney, MBBS
Results of the ENZAMET trial showed that enzalutamide (Xtandi) significantly improved overall survival (OS) when added to the standard of care for patients with metastatic hormone-sensitive prostate cancer, although the benefits were lower for those slated to receive early docetaxel, explained Christopher Sweeney, MBBS.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x